Hodgkin Disease

"Hodgkin Disease" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.

Descriptor ID	D006689
MeSH Number(s)	C04.557.386.355 C15.604.515.569.355 C20.683.515.761.355
Concept/Terms	Hodgkin Disease Hodgkin Disease Disease, Hodgkin Granuloma, Hodgkin's Hodgkin's Granuloma Granuloma, Hodgkins Hodgkins Granuloma Lymphogranuloma, Malignant Lymphogranulomas, Malignant Malignant Lymphogranuloma Malignant Lymphogranulomas Hodgkin Lymphoma Lymphoma, Hodgkin Hodgkin's Disease Disease, Hodgkin's Hodgkin's Lymphoma Hodgkins Lymphoma Lymphoma, Hodgkin's Hodgkins Disease Disease, Hodgkins Granuloma, Hodgkin Hodgkin Granuloma Granuloma, Malignant Malignant Granuloma Malignant Granulomas Nodular Lymphocyte-Predominant Hodgkin's Lymphoma Nodular Lymphocyte-Predominant Hodgkin's Lymphoma Nodular Lymphocyte Predominant Hodgkin's Lymphoma Nodular Sclerosing Hodgkin's Lymphoma Lymphocyte-Rich Classical Hodgkin's Lymphoma Lymphocyte-Rich Classical Hodgkin's Lymphoma Lymphocyte Rich Classical Hodgkin's Lymphoma Mixed Cellularity Hodgkin's Lymphoma Mixed Cellularity Hodgkin's Lymphoma Hodgkin Lymphoma, Adult Hodgkin Lymphoma, Adult Adult Hodgkin Lymphoma Lymphocyte Depletion Hodgkin's Lymphoma Lymphocyte Depletion Hodgkin's Lymphoma

Below are MeSH descriptors whose meaning is more general than "Hodgkin Disease".

Diseases [C]
Neoplasms [C04]
Neoplasms by Histologic Type [C04.557]
Lymphoma [C04.557.386]
Hodgkin Disease [C04.557.386.355]
Hemic and Lymphatic Diseases [C15]
Lymphatic Diseases [C15.604]
Lymphoproliferative Disorders [C15.604.515]
Lymphoma [C15.604.515.569]
Hodgkin Disease [C15.604.515.569.355]
Immune System Diseases [C20]
Immunoproliferative Disorders [C20.683]
Lymphoproliferative Disorders [C20.683.515]
Lymphoma [C20.683.515.761]
Hodgkin Disease [C20.683.515.761.355]

Below are MeSH descriptors whose meaning is related to "Hodgkin Disease".

Below are MeSH descriptors whose meaning is more specific than "Hodgkin Disease".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Hodgkin Disease" by people in this website by year, and whether "Hodgkin Disease" was a major or minor topic of these publications.

Bar chart showing 22 publications over 13 distinct years, with a maximum of 4 publications in 2008

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2001	1	0	1
2002	0	1	1
2003	2	0	2
2004	1	0	1
2005	2	0	2
2006	3	0	3
2007	1	0	1
2008	4	0	4
2011	2	0	2
2012	2	0	2
2017	1	0	1
2018	1	0	1
2019	1	0	1

Below are the most recent publications written about "Hodgkin Disease" by people in Profiles.

Cohen JB, Wei L, Maddocks KJ, Christian B, Heffner LT, Langston AA, Lechowicz MJ, Porcu P, Flowers CR, Devine SM, Blum KA. Gemcitabine and bendamustine is a safe and effective salvage regimen for patients with recurrent/refractory Hodgkin lymphoma: Results of a phase 1/2 study. Cancer. 2020 03 15; 126(6):1235-1242.

View in: PubMed
Jain S, Gupta A, Nagalla S. A Mediastinal Mass in a Young Man. JAMA. 2018 06 19; 319(23):2432-2433.

View in: PubMed
Mikkilineni L, Whitaker-Menezes D, Domingo-Vidal M, Sprandio J, Avena P, Cotzia P, Dulau-Florea A, Gong J, Uppal G, Zhan T, Leiby B, Lin Z, Pro B, Sotgia F, Lisanti MP, Martinez-Outschoorn U. Hodgkin lymphoma: A complex metabolic ecosystem with glycolytic reprogramming of the tumor microenvironment. Semin Oncol. 2017 06; 44(3):218-225.

View in: PubMed
Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Aoun P, Bello CM, Bierman PJ, Blum KA, Chen R, Dabaja B, Duron Y, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hochberg EP, Maloney DG, Mansur D, Mauch PM, Metzger M, Moore JO, Morgan D, Moskowitz CH, Poppe M, Pro B, Winter JN, Yahalom J, Sundar H. Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2012 May; 10(5):589-97.

View in: PubMed
Younes A, Oki Y, McLaughlin P, Copeland AR, Goy A, Pro B, Feng L, Yuan Y, Chuang HH, Macapinlac HA, Hagemeister F, Romaguera J, Samaniego F, Fanale MA, Dabaja BS, Rodriguez MA, Dang N, Kwak LW, Neelapu SS, Fayad LE. Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma. Blood. 2012 May 3; 119(18):4123-8.

View in: PubMed
Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Bello CM, Bierman PJ, Blum KA, Dabaja B, Duron Y, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hochberg EP, Maloney DG, Mansur D, Mauch PM, Metzger M, Moore JO, Morgan D, Moskowitz CH, Poppe M, Pro B, Weiss L, Winter JN, Yahalom J. Hodgkin lymphoma. J Natl Compr Canc Netw. 2011 Sep 1; 9(9):1020-58.

View in: PubMed
Fanale M, Fayad L, Pro B, Samaniego F, Liboon MJ, Nunez C, Horowitz S, Anderlini P, Popat U, Ji Y, Kwak LW, Younes A. Phase I study of bortezomib plus ICE (BICE) for the treatment of relapsed/refractory Hodgkin lymphoma. Br J Haematol. 2011 Jul; 154(2):284-6.

View in: PubMed
Bar Ad V, Paltiel O, Glatstein E. Radiotherapy for early-stage Hodgkin's lymphoma: a 21st century perspective and review of multiple randomized clinical trials. Int J Radiat Oncol Biol Phys. 2008 Dec 1; 72(5):1472-9.

View in: PubMed
Hoppe RT, Advani RH, Ambinder RF, Bierman PJ, Bloomfield CD, Blum K, Dabaja B, Djulbegovic B, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hudson MM, Kaminski MS, Love G, Maloney DG, Mansur D, Mauch PM, Moore JO, Schilder RJ, Weiss LM, Winter JN, Yahalom J, Zelenetz AD. Hodgkin disease/lymphoma. J Natl Compr Canc Netw. 2008 Jul; 6(6):594-622.

View in: PubMed
Oki Y, Pro B, Fayad LE, Romaguera J, Samaniego F, Hagemeister F, Neelapu S, McLaughlin P, Goy A, Younes A. Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma. Cancer. 2008 Feb 15; 112(4):831-6.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement